EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS

EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS

Objective: To study the time course of changes in the indices of the blood lipid spectrum in patients with rheumatoid arthritis (RA) treated with rituximab during a 24-week follow-up. Subjects and methods. The study enrolled 39 patients (36 females and 3 males) with a valid diagnosis of RA; their me...

Full description

Bibliographic Details
Main Authors:	Tatyana Valentinovna Popkova, D S Novikova, O G Lineva, A A Novikov, E N Aleksandrova, E L Nasonov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2010-08-01
Series:	Научно-практическая ревматология
Subjects:	rheumatoid arthritis chronic inflammation blood lipid spectrum rituximab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1076

Similar Items

ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS
by: A. A. Novikov, et al.
Published: (2011-06-01)

CHANGES IN HEART RATE, HEART RATE VARIABILITY AND QT INTERVAL IN WOMEN WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB TREATMENT
by: D. S. Novikova, et al.
Published: (2014-06-01)

Efficacy of Rituximab on Rheumatoid Leptomeningitis as the First Symptom of Rheumatoid Arthritis
by: Mickaël Chouk, et al.
Published: (2021-04-01)

Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment
by: Ulusoy H, et al.
Published: (2020-09-01)

The Impact of Rituximab Therapy on the Chromosomes of Patients with Rheumatoid Arthritis
by: Šekib Sokolović, et al.
Published: (2010-05-01)

Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
by: E. L. Nasonov, et al.
Published: (2016-12-01)

PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01)

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01)

Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis
by: Aleksandr Vital'evich Volkov, et al.
Published: (2010-12-01)

EFFECT OF RITUXIMAB ON CARDIAC ELECTROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: L. I. Feiskhanova
Published: (2018-11-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01)

Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis
by: Levent Kilic, et al.
Published: (2018-11-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

Rituximab treatment of rheumatoid arthritis: new evidence
by: E L Nasonov, et al.
Published: (2009-06-01)

Pancytopenia following rituximab therapy in a patient with rheumatoid arthritis: Could filgrastim be a temporary solution?
by: Robin George Manappallil
Published: (2016-08-01)

Administration of monoclonal antibodies to b-lymphocytes (rituximab) in rheumatoid arthritis in Russia
by: E L Nasonov, et al.
Published: (2008-08-01)

Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy
by: Maurizio Benucci, et al.
Published: (2009-03-01)

THE EFFICACY AND SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: D. A. Kusevich, et al.
Published: (2017-09-01)

Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2019-07-01)

Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-08-01)

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report
by: Gerasimos Evangelatos, et al.
Published: (2017-01-01)

Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)
by: A. S. Avdeeva, et al.
Published: (2019-03-01)

RITUXIMAB THERAPY MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS HROUGH PERIPHERAL BLOOD GENE EXPRESSION ANALYSIS
by: E. V. Chetina, et al.
Published: (2014-06-01)

Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia
by: A. S. Avdeeva, et al.
Published: (2020-05-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

Quality of life in patients with rheumatoid arthritis during rituximab therapy
by: Tatiana Alekseyevna Raskina, et al.
Published: (2013-06-01)

Quality of life in patients with rheumatoid arthritis during rituximab therapy
by: Tatiana Alekseyevna Raskina, et al.
Published: (2013-06-01)

Sustained drug-free remission and persistent hypogammaglobulinemia in a patient with rheumatoid arthritis three years after discontinuing Rituximab treatment
by: Marco Krasselt, et al.
Published: (2021-04-01)

TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
by: A V Bezgin, et al.
Published: (2011-08-01)

The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis
by: A S Avdeeva, et al.
Published: (2019-05-01)

Assessing Efficacy, Safety and Tolerability of Rituximab for Rheumatoid Arthritis: Meta-Analyses of Randomized Controlled Trials
by: Rafael Venson, et al.
Published: (2013-12-01)

Six month assessment of low dose rituximab in the treatment of rheumatoid arthritis during coronavirus disease 2019 (COVID-19) pandemic
by: Yunus Durmaz, et al.
Published: (2021-06-01)

THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: A. S. Avdeeva, et al.
Published: (2017-07-01)

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AS A COMPLICATION OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS (A CASE REPORT)
by: I. B. Bashkova, et al.
Published: (2018-09-01)

Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study
by: L. Bazzichi, et al.
Published: (2014-11-01)

Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab
by: Daniela Viecceli, et al.

Rituximab used for simultaneous treatment of PR3‐ANCA positive vasculitis associated with rheumatoid arthritis: A case report
by: Akihiro Yamada, et al.
Published: (2020-12-01)

18F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab
by: Pacôme FOSSE, et al.
Published: (2018-02-01)

CHANGES OF BONE MINERAL DENSITY DURING FOUR-YEAR RITUXIMAB AND METHOTREXATE THERAPY IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS
by: T. A. Raskina, et al.
Published: (2016-12-01)